Lumos Pharma, Inc. (LUMO)
NASDAQ: LUMO · IEX Real-Time Price · USD
2.590
-0.030 (-1.15%)
Apr 19, 2024, 4:00 PM EDT - Market closed
Lumos Pharma Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Lumos Pharma stock have an average target of 18, with a low estimate of 10 and a high estimate of 28. The average target predicts an increase of 594.98% from the current stock price of 2.59.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 20, 2024.
Analyst Ratings
The average analyst rating for Lumos Pharma stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $28 | Strong Buy | Reiterates | $28 | +981.08% | Mar 20, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $16 | Buy | Maintains | $16 | +517.76% | Mar 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $28 | Strong Buy | Reiterates | $28 | +981.08% | Mar 8, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $17 → $16 | Buy | Maintains | $17 → $16 | +517.76% | Dec 11, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $28 | Strong Buy | Reiterates | $28 | +981.08% | Dec 7, 2023 |
Financial Forecast
Revenue This Year
8.99M
from 2.05M
Increased by 338.13%
Revenue Next Year
8.81M
from 8.99M
Decreased by -1.94%
EPS This Year
-2.87
from -4.18
EPS Next Year
-2.05
from -2.87
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 42.0M | 41.1M | 103.5M | 202.1M | 335.2M |
| Avg | 9.0M | 8.8M | 28.8M | 127.3M | 325.6M |
| Low | n/a | n/a | n/a | 55.9M | 312.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 1,947.8% | 357.4% | 1,074.8% | 601.0% | 163.4% |
| Avg | 338.1% | -1.9% | 227.2% | 341.3% | 155.9% |
| Low | - | - | - | 93.7% | 145.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.53 | -1.72 | 2.28 | 7.78 | 14.97 |
| Avg | -2.87 | -2.05 | -0.88 | 7.56 | 14.55 |
| Low | -4.74 | -2.34 | -2.35 | 7.26 | 13.97 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 98.1% |
| Avg | - | - | - | - | 92.4% |
| Low | - | - | - | - | 84.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.